Figure 3

Effect of Tlx1 overexpression in situ in the spleen on BM hematopoiesis. Tlx1^CreER-Venus littermate controls and Tlx1^CreER-Venus; R26^Tlx1 mice (4-week-old) were treated with tamoxifen and hematopoietic cell populations in the BM and the peripheral blood were analyzed 8 weeks after the final treatment. Data were pooled from 4 independent experiments. (a) Total numbers of the indicated hematopoietic stem/progenitor cell populations in the BM of tamoxifen-treated Tlx1^CreER-Venus controls (Ctr) and tamoxifen-treated Tlx1^CreER-Venus; R26^Tlx1 mice (Tg). (mean ± SD; n = 6). (b) Total numbers of the indicated mature hematopoietic cell populations in the BM of tamoxifen-treated Tlx1^CreER-Venus controls (Ctr) and tamoxifen-treated Tlx1^CreER-Venus; R26^Tlx1 mice (Tg). (mean ± SD; n = 6). (c) Hematological indices of peripheral blood of tamoxifen-treated Tlx1^CreER-Venus controls (Ctr) and tamoxifen-treated Tlx1^CreER-Venus; R26^Tlx1 mice (Tg). RBC indicates red blood cell count; WBC, white blood cell count; Platelets, platelet cell count; HCT, hematocrit; Hb, hemoglobin. (mean ± SD; n = 6).